drugset / Trial / NCT05138575
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
RandomizedCrossoverQuadruple-blindTreatment
Summary
This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism \[Empagliflozin (Empa)\], with and without additional supplements that increase perfusion and fatty acid oxidation \[Potassium Nitrate (KNO3)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Timeline
- Start
- 2022-01-24
- Primary completion
- 2027-05-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Empagliflozin | Small molecule | 10 mg | — |
| Comparator | Potassium Chloride | Small molecule | 6 mmol | — |
| Comparator | Potassium Nitrate | Other / unclassified | 6 mmol | — |